Combined Immune Checkpoint Blockade

被引:12
|
作者
Drake, Charles G. [1 ,2 ,3 ,4 ]
机构
[1] James Buchanan Brady Urol Inst, Dept Oncol, Baltimore, MD USA
[2] James Buchanan Brady Urol Inst, Dept Urol, Baltimore, MD USA
[3] Johns Hopkins Univ, Sch Med, Baltimore, MD USA
[4] Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA
关键词
ACTIVATED T-CELLS; CANCER-IMMUNOTHERAPY; EFFECTOR FUNCTION; OVARIAN-CANCER; REGULATORY T; LAG-3; PD-1; IPILIMUMAB; AUTOIMMUNE; TIM-3;
D O I
10.1053/j.seminoncol.2015.05.002
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
There are very few tumor types for which chemotherapy regimens are regularly curative; notable exceptions include testicular cancer and Hodgkin's lymphoma. In both cases combination chemotherapy approaches are required. Thus, it would seem only logical that combination immunotherapy approaches will be required to induce long-term remissions in the majority of cancer patients. Immune checkpoint blockade can be combined with several other interventions, including radiation therapy, chemotherapy and cancer vaccines. However, the observation that T cells that are rendered not-responsive or "exhausted" by recognition of tumor antigens express multiple non-overlapping checkpoint molecules suggests that immunotherapy approaches in which multiple checkpoint molecules are blocked may be particularly active in the clinic. (C) 2015 Elsevier Inc. All rights reserved.
引用
收藏
页码:656 / 662
页数:7
相关论文
共 50 条
  • [2] Antiangiogenic therapy combined with immune checkpoint blockade in renal cancer
    Teele Kuusk
    Laurence Albiges
    Bernard Escudier
    Nikolaos Grivas
    John Haanen
    Thomas Powles
    Axel Bex
    [J]. Angiogenesis, 2017, 20 : 205 - 215
  • [3] Combined radiation therapy and immunotherapy including blockade of immune checkpoint
    Akimoto, Tetsuo
    [J]. ANNALS OF ONCOLOGY, 2018, 29
  • [4] Antiangiogenic therapy combined with immune checkpoint blockade in renal cancer
    Kuusk, Teele
    Albiges, Laurence
    Escudier, Bernard
    Grivas, Nikolaos
    Haanen, John
    Powles, Thomas
    Bex, Axel
    [J]. ANGIOGENESIS, 2017, 20 (02) : 205 - 215
  • [5] Radiotherapy combined with immune checkpoint blockade immunotherapy: Achievements and challenges
    Teng, Feifei
    Kong, Li
    Meng, Xiangjiao
    Yang, Jia
    Yu, Jinming
    [J]. CANCER LETTERS, 2015, 365 (01) : 23 - 29
  • [6] Immune Checkpoint Blockade
    Naidoo, Jarushka
    Page, David B.
    Wolchok, Jedd D.
    [J]. HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2014, 28 (03) : 585 - +
  • [7] PARP Inhibition Combined with Immune Checkpoint Blockade in SCLC: Oasis in an Immune Desert or Mirage?
    Gay, Carl M.
    Byers, Lauren A.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (08) : 1323 - 1326
  • [8] IDO Inhibition potentiates the Effects of combined Radiotherapy and Immune Checkpoint Blockade
    Watanabe, T.
    Niedermann, G.
    [J]. STRAHLENTHERAPIE UND ONKOLOGIE, 2019, 195 : S45 - S46
  • [9] Combined Immune Checkpoint Blockade in Mesothelioma: In Vivo Investigation of in Vitro Data
    Marcq, E.
    Van Audenaerde, J.
    De Waele, J.
    Jacobs, J.
    Van Loenhout, J.
    Pauwels, P.
    Smits, E.
    Van Meerbeeck, J.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S725 - S725
  • [10] Combined Radiation Therapy and Immune Checkpoint Blockade Therapy for Breast Cancer
    Hu, Zishuo I.
    Ho, Alice Y.
    McArthur, Heather L.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2017, 99 (01): : 153 - 164